Skip NavigationSkip to Content

Analysis of Pro-inflammatory Cytokine and Type II Interferon Induction by Nanoparticles

  1. Author:
    Potter, Tim
    Neun, Barry
    Rodriguez, Jamie
    Ilinskaya, Anna N
    Dobrovolskaia, Marina
  2. Author Address

    Cancer Research Technology Program, Nanotechnology Characterization Laboratory, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, P.O. Box B, Frederick, MD, 21702, USA., Cancer Research Technology Program, Nanotechnology Characterization Laboratory, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, P.O. Box B, Frederick, MD, 21702, USA. marina@mail.nih.gov.,
    1. Year: 2018
  1. Journal: Methods in molecular biology (Clifton, N.J.)
    1. 1682
    2. Pages: 173-187
  2. Type of Article: Article
  1. Abstract:

    Cytokines, chemokines, and interferons are released by the immune cells in response to cellular stress, damage and/or pathogens, and are widely used as biomarkers of inflammation. Certain levels of cytokines are needed to stimulate an immune response in applications such as vaccines or immunotherapy where immune stimulation is desired. However, undesirable elevation of cytokine levels, as may occur in response to a drug or a device, may lead to severe side effects such as systemic inflammatory response syndrome or cytokine storm. Therefore, preclinical evaluation of a test material 39;s propensity to cause cytokine secretion by healthy immune cells is an important parameter for establishing its safety profile. Herein, we describe in vitro methods for analysis of cytokines, chemokines, and type II interferon in whole blood cultures derived from healthy donor volunteers. First, whole blood is incubated with controls and tested nanomaterials for 24 160;h. Then, culture supernatants are analyzed by ELISA to detect IL-1ß, TNFa, IL-8, and IFN?. The culture supernatants can also be analyzed for the presence of other biomarkers secreted by the immune cells. Such testing would require additional assays not covered in this chapter and/or optimization of the test procedure to include relevant positive controls and/or cell types.

    See More

External Sources

  1. DOI: 10.1007/978-1-4939-7352-1_15
  2. PMID: 29039102

Library Notes

  1. Fiscal Year: FY2017-2018
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel